C反应蛋白 flare 可预测黑色素瘤免疫检查点抑制剂治疗反应
该研究基于两个前瞻性队列(晚期黑色素瘤 n=87,完全切除黑色素瘤 n=99),按免疫检查点抑制剂启动后早期 CRP 动力学将患者分为 CRP flare、CRP 应答者和 CRP 无应答者,发现早期 CRP 动力学与改善的 OS 及 RFS/PFS 相关。
要点
- CRP flare 定义为 30 天内基线 CRP 翻倍且 3 个月内下降至少 30%。
- 晚期队列中 CRP 应答者较无应答者进展风险独立降低 62%(p=0.001)。
- 早期 CRP 动力学或可辅助识别 ICI 治疗获益的黑色素瘤患者。
核心结论
- 早期 CRP 动力学可提示黑色素瘤患者对 ICI 的应答,并与改善的 OS 和 RFS/PFS 相关。
- CRP flare 和 CRP 应答者较 CRP 无应答者结局显著改善。
研究设计与样本
- 分析两个独立前瞻性收集的队列:队列1为晚期黑色素瘤(n=87),队列2为完全切除的黑色素瘤(n=99)。
- 按 ICI 启动后 CRP 动力学分层:30 天内基线 CRP 翻倍且 3 个月内下降至少 30% 为 CRP flare;无翻倍但 3 个月内下降 30% 为 CRP 应答者;其余为 CRP 无应答者。
- 分析因素包括 S100B 和 LDH 等临床特征;队列1和队列2的中位随访分别为 1.5 年和 1.7 年。
主要发现
- 队列1中 CRP flare(n=12)、CRP 应答者(n=43)和 CRP 无应答者(n=32)的 PFS 分别为 0.7、0.6 和 0.2 年(p=0.017)。
- 队列1中三组的 OS 分别为 2.2、1.5 和 1.0 年(p=0.014)。
- 多变量 Cox 分析显示,CRP 应答者较 CRP 无应答者进展风险独立降低 62%(p=0.001)。
- 队列2中 CRP flare(n=13)、CRP 应答者(n=70)和 CRP 无应答者(n=16)的 OS 与 RFS 曲线 log-rank 分析差异显著(p=0.046 和 p=0.049)。
关键数值与推荐
- CRP flare:ICI 启动后 30 天内基线 CRP 翻倍,随后 3 个月内下降至少 30%。
- CRP 应答者:无 CRP 翻倍,但 3 个月内 CRP 下降至少 30%。
- CRP 无应答者:不符合上述 CRP flare 或 CRP 应答标准者。
临床怎么用
- 在黑色素瘤患者启动 ICI 治疗后,可监测早期 CRP 动力学(30 天内翻倍及 3 个月内下降幅度)以辅助判断治疗应答。
- CRP flare 或 CRP 应答提示较 CRP 无应答者更好的 OS 及 RFS/PFS,可结合 S100B、LDH 等临床特征综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of melanoma has been revolutionized by the use of immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune-related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify patients benefitting. In lung, renal cell and bladder cancer early C-reactive protein (CRP) kinetics were shown to be a predictive biomarker for ICI. OBJECTIVE: Here, we investigate early CRP kinetics as predictive biomarker for ICI in melanoma patients. METHODS: Two independent prospectively collected cohorts were analysed: Cohort 1 (n = 87) with advanced and Cohort 2 (n = 99) with completely resected melanoma. Patients were stratified by in the dynamics of CRP after ICI initiation: A doubling of baseline CRP within 30 days followed by at least a 30% drop within 3 months was classified as a CRP flare. If no doubling of CRP was reported, but a 30% drop within 3 months, patients were classified as CRP responders and all others as CRP non-responders. Analysed factors included clinical characteristics like S100B and LDH. Median follow-up was 1.5 and 1.7 years for Cohorts 1 and 2. RESULTS: In Cohort 1 CRP flare (n = 12), CRP responders (n = 43) and CRP non-responders (n = 32) with a progression-free survival (PFS) of 0.7, 0.6 and 0.2 years (p = 0.017) and an overall survival (OS) of 2.2, 1.5 and 1.0 years (p = 0.014), respectively. Multivariable Cox analysis showed an independent risk reduction of progression for CRP responders by 62% compared to CRP non-responders (p = 0.001). In Cohort 2 CRP flare (n = 13), CRP responders (n = 70) and CRP non-responders (n = 16) the log-rank analysis showed a significant difference between OS and recurrence-free survival (RFS) curves (p = 0.046 and p = 0.049). CONCLUSION: Early CRP kinetics could indicate a response to ICI with improved OS and RFS/PFS. CRP flare and CRP response indicating significantly improved outcomes compared to CRP non-responders.
引用
- Kött J, Zimmermann N, Zell T, et al. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma. J Eur Acad Dermatol Venereol. 2024. PMID: 38466133. doi:10.1111/jdv.19941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。